Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PMM2 | O15305 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643464 | 0.81 | PTPN1 (0.66) | PTPN1MAPTMEN1KMT2A | |
| SCHEMBL6684475 | 0.81 | PTPN1 (0.66) | PTPN1ALOX5L3MBTL1MGLLMEN1 | |
| SCHEMBL1731203 | 0.81 | PTPN1 (0.66) | PTPN1MGLLMPI | |
| SCHEMBL15158748 | 0.81 | PTPN1 (0.60) | PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL1688165 | 0.80 | PTPN1 (0.69) | PTPN1ALOX5L3MBTL1MAPTMGLL | |
| SCHEMBL6690418 | 0.80 | PTPN1 (0.73) | PTPN1HSD17B10HSP90AA1MGLL | |
| SCHEMBL1732116 | 0.80 | PTPN1 (1.00) | PTPN1ALOX5MAPTMEN1GAA | |
| SCHEMBL1731402 | 0.78 | PTPN1 (0.96) | PTPN1ALOX5MAPTMEN1GAA | |
| SCHEMBL1732288 | 0.78 | PTPN1 (0.65) | PTPN1L3MBTL1MAPTHSD17B10MEN1 | |
| SCHEMBL3609861 | 0.78 | PTPN1 (0.60) | PTPN1ALOX5L3MBTL1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| WO-2012046869-A1 | CYCLIC AMIDE DERIVATIVE | 持田製薬株式会社 (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | PTPN1 533/4885ALOX5 3188/4885L3MBTL1 3286/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | PTPN1 550/4885ALOX5 3230/4885L3MBTL1 3203/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | PTPN1 811/4885ALOX5 3086/4885L3MBTL1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.